Hepatocellular Carcinoma in Primary Biliary Cholangitis

Alexander M Sy; Raphaella D Ferreira; Binu V John

doi:10.1016/j.cld.2022.06.011

Hepatocellular Carcinoma in Primary Biliary Cholangitis

Clin Liver Dis. 2022 Nov;26(4):691-704. doi: 10.1016/j.cld.2022.06.011.

Authors

Alexander M Sy¹, Raphaella D Ferreira², Binu V John²

Affiliations

¹ Division of Hepatology, Miami VA Medical System, Department of Medicine, University of Miami Miller School of Medicine, 1201 Northwest 16th Street, Miami, FL 33125, USA; Department of Translational Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, FL, USA. Electronic address: alexander.sy3@va.gov.
² Division of Hepatology, Miami VA Medical System, Department of Medicine, University of Miami Miller School of Medicine, 1201 Northwest 16th Street, Miami, FL 33125, USA.

PMID: 36270724
DOI: 10.1016/j.cld.2022.06.011

Abstract

Hepatocellular carcinoma (HCC) is potentially fatal complication affecting patients with primary biliary cholangitis (PBC). The incidence of HCC is 13 per 1000 person-years in patients with PBC cirrhosis, but much lower at 2.7 per 1000 person-years among patients with PBC without cirrhosis. Risk factors for the development of HCC in PBC include the presence of advanced fibrosis or cirrhosis and male sex, with some studies suggesting that treatment with ursodeoxycholic acid (UDCA) and UDCA response may reduce risk.

Keywords: Autoimmune liver disease; Cirrhosis; Epidemiology; Primary liver cancer.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular* / epidemiology
Carcinoma, Hepatocellular* / etiology
Cholagogues and Choleretics / therapeutic use
Cholangitis*
Humans
Liver Cirrhosis, Biliary* / complications
Liver Cirrhosis, Biliary* / drug therapy
Liver Cirrhosis, Biliary* / epidemiology
Liver Neoplasms* / epidemiology
Liver Neoplasms* / etiology
Male
Ursodeoxycholic Acid / therapeutic use

Substances

Ursodeoxycholic Acid
Cholagogues and Choleretics